Source: DGNews  |  Posted 8 years ago

By Charlene Laino

NEW YORK, NY -- October 6, 2003 -- Final analyses of three phase I studies suggest that Merck's HIV-1 gag DNA vaccine for the prevention of HIV-1 infection elicits specific antiviral cellular immune responses, with the 5 mg dose showing better immunogenicity than the 1 mg dose.

The vaccine was also well tolerated, said Emilio A. Emini, PhD, senior vice president of vaccine research at Merck Research Labs in West Point, Pennsylvania, United States. However, contrary to what was demonstrated in rhesus monkeys, the addition of adjuvants